İleri Dönem Romatoid Artrit Ra Hastalarında Anti-Siklik Sitrülinlenmiş Peptid Anti-Ccp Antikorunun Hastalık Aktivitesi İle İlişkisi Ve Prognostik Değeri

Öz

Amaç: Anti-siklik sitrülinlenmiş peptid anti-CCP antikorları romatoid artrit RA tanısında son yıllarda kullanılmaya başlanmış yüksek özgüllük ve duyarlılığa sahip belirteçlerdir. Bu çalışmada ileri dönem RA hastalarında anti-CCP antikorlarının hastalık aktivitesi, radyolojik olarak saptanan eklem hasarı ile ilişkisinin ve prognostik değerinin araştırılması amaçlanmıştır.Yöntem: İleri dönem 122 RA hastası ve 50 sağlıklı kontrolde anti-CCP antikoru ve romatoid faktör RF titreleri ölçülmüştür. Hastalık aktivitesinin değerlendirilmesinde; hassas eklem sayısı HES , şiş eklem sayısı ŞES , vizuel analog skala VAS ’ya göre ağrı şiddeti, sabah tutukluğu süresi, hastaya ve hekime göre global hastalık aktivitesi skoru, 28 eklemde hastalık aktivesi skoru DAS 28 , eritrosit sedimantasyon hızı ESH , lökosit sayısı, C-reaktif protein CRP düzeyi kullanılmıştır. Fonksiyonel aktivite sorgulanması Health Assessment Questionnaire HAQ , eklem hasarının radyolojik değerlendirilmesi Larsen Yöntemi ile yapılmıştır.Bulgular: Hastaların %66.4’ünde anti-CCP antikoru, %59’unda RF pozitif bulunmuştur. RA hastalarında; anti-CCP titresi ile RF titresi r=0.582, p

Anahtar Kelimeler

• Romatoid artrit, anti-CCP antikoru, romatoid faktör, prognoz, hastalık aktivitesi

Association of anti-cyclic citrulinated peptide anti-CCP antibody with disease activity in advanced rheumatoid arthritis patients and its prognostic value

Öz

Objective: Anti-cyclic citrullinated peptide anti-CCP antibodies are highly specific and sensitive markers which are used in the diagnosis of rheumatoid arthritis RA , in recent years. In this study it was aimed to investigate the association of anti-CCP antibodies with disease activity and radiological joint damage in advanced RA patients and the prognostic value of anti-CCP antibodies. Method: Titers of anti- CCP antibodies and rheumatoid factor RF in 122 advanced RA patients and 50 healthy controls had been searched. In order to determine the activity of the disease , tender joints count TJC , swollen joints count SJC , visual analog scale VAS for pain, duration of morning stiffness, patient’s and physician’s global assessment, disease activity score for 28 joints DAS 28 , erythrocyte sedimentation rate ESR , leukocyte count and C-reactive protein CRP were evaluated. Functional activity assessment and radiological joint damage were carried out according to the Health Assessment Questionnaire HAQ and Larsen method, respectively.Results: 66.4% were positive for anti-CCP antibodies and 59% were positive for RF of the patients. In patients with RA, significant correlations were found between serum anti-CCP level and RF level r=0.582, p

Anahtar Kelimeler

• Rheumatoid arthritis, anti-CCP antibody, rheumatoid factor, prognosis, disease activity

Kaynakça

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med. 1990; 322(18): 1277-89.
2. Gümüşdiş G. Romatoid artrit. Gümüşdiş G, Doğanavşargil E (editörler). Klinik Romatoloji. İstanbul: Deniz Matbaası 1999; 269-78.
3. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiol Rev. 1981;3: 27-44.
4. Buch M, Emery P. The aetiology and pathogenesis of rheumatoid arthritis. Hosp Pharm 2002; 9: 5-10.
5. Weissmann G. Pathogenesis of rheumatoid arthritis. J Clin Rheumatol. 2004 ;10(3 Suppl): S26-31.
6. Griesmacher A, Peichl P. Autoantibodies associated with rheumatic diseases. Clin Chem Lab Med. 2001 ; 39(3): 189-208.
7. Kastbom A, Strandberg G, Lindroos A, Skogh T. AntiCCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis. 2004 ;63(9): 1085-9.
8. del Val del Amo N, Ibanez Bosch R, Fito Manteca C, Gutierrez Polo R, Loza Cortina E. Anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: relation with disease aggressiveness. Clin Exp Rheumatol. 2006; 24(3): 281-6.

9. van Venrooij WJ, Pruijn GJ. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res. 2000;2(4): 249-51. Epub 2000 May 24.
10. Khosla P, Shankar S, Duggal L. Anti CCP antibodies in rheumatoid arthritis. J Indian Rheumatol Assoc 2004 : 12 : 143 -46.
11. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med. 2002; 60(10): 383-8.
12. López-Hoyos M, Marquina R, Tamayo E et al. Defects in the regulation of B cell apoptosis are required for the production of citrullinated peptide autoantibodies in mice. Arthritis Rheum. 2003; 48(8):2353-61.
13. Vossenaar ER, Nijenhuis S, Helsen MM et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum. 2003; 48(9): 2489-500.
14. Zhou Z, Ménard HA. Autoantigenic posttranslational modifications of proteins: does it apply to rheumatoid arthritis? Curr Opin Rheumatol. 2002; 14(3): 250-3.
15. Suzuki A, Yamada R, Chang X et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet. 2003; 34(4): 395-402.
16. Schellekens GA, de Jong BAW, Van den Hoogen FHJ, Van de PutteLBA, Van Venrooij WJ. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998, 101(1): 273–81.
17. Sebbag M, Simon M, Vincent C et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest. 1995; 95(6): 2672-9.
18. Schellekens GA, Visser H, de Jong BA et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000 43(1): 155-63.
19. Zendman AJ, van Venrooij WJ, Pruijn GJ. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford). 2006; 45(1): 20-5.
20. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis. 2003; 62(9): 870–4.
21. Suzuki K, Sawada T, Murakami A et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol. 2003; 32(4): 197–204.
22. Vasishta A. Diagnosing early-onset rheumatoid arthritis: the role of anti-CCP antibodies. Am Clin Lab. 2002; 21(7): 34–6.
23. Pinheiro GC, Scheinberg M A, Aparecida da Silva M, Maciel S. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med. 2003; 139(3): 234–5.
24. Rantapää-Dahlqvist S, de Jong BA, Berglin E et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 2003; 48(10): 2741–9.
25. Kroot EJ, de Jong BA, van Leeuwen MA et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000; 43(8): 1831-5.
26. Nielen MM, van Schaardenburg D, Reesink HW et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 2004; 50(2): 380-6.
27. Visser H, le Cessie S, Vos K, Breedveld FC, Hazes JMW. How to diagnose rheumatoid arthritis early; a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46: 357-65.
28. van Gaalen FA, Linn-Rasker SP, van Venrooij WJ et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum. 2004; 50(3): 709-15.
29. Goldbach-Mansky R, Lee J, McCoy A et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res. 2000; 2(3): 236- 43.
30. Bukhari M, Harrison B, Lunt M, Scott DG, Symmons DP, Silman AJ. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis Rheum. 2001; 44(6): 1248-53.
31. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988; 31(3): 315-24.
32. Smolen JS, Breedveld FC, Eberl G et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. Arthritis Rheum. 1995; 38(1): 38-43.
33. Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G. Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther. 1983; 34(2): 234-9.
34. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1): 44-8.
35. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2): 137-45.
36. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis. 2001; 60(9): 817-27.
37. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn (Stockh). 1977; 18(4): 481-91.
38. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. J Rheumatol. 1995; 22(10): 1974-5.
39. Mimori T. Clinical significance of anti-CCP antibodies in rheumatoid arthritis. Intern Med. 2005; 44(11): 1122-6.
40. Mikuls TR, O'Dell JR, Stoner JA et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum. 2004; 50(12): 3776-82.
41. Bobbio-Pallavicini F, Alpini C, Caporali R, Avalle S, Bugatti S, Montecucco C. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther. 2004; 6(3): R264-72.
42. De Rycke L, Peene I, Hoffman IE et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004; 63(12): 1587-93.
43. Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K. Diagnostic and clinical value of anticyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis. 2004; 63(9): 1079-84.
44. Zeng X, Ai M, Tian X et al. Diagnostic value of anticyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol. 2003; 30(7): 1451-5.
45. Inanc N, Dalkilic E, Kamali S et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol. 2007; 26(1): 17-23.
46. Bongi SM, Manetti R, Melchiorre D et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis antiCCP and bone damage in RA. Autoimmunity. 2004; 37(6-7): 495-501.
47. Forslind K, Ahlmen M, Eberhardt K, Hafstrom I, Svensson B; BARFOT Study Group. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis. 2004; 63(9): 1090-5.
48. Ronnelid J, Wick MC, Lampa J et al. Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis. 2005; 64(12): 1744-9.
49. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol. 2004; 16(3): 246-53.
50. Masi AT, Maldonado-Cocco JA, Kaplan SB, Feigenbaum SL, Chandler RW. Prospective study of the early course of rheumatoid arthritis in young adults: comparison of patients with and without rheumatoid factor positivity at entry and identification of variables correlating with outcome. Semin Arthritis Rheum. 1976; 4(4): 299-326.
51. van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther. 2005; 7(5): R949-58
52. Bas S, Genevay S, Meyer O, Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford). 2003; 42(5): 677-80.
53. Samanci N, Ozdem S, Akbas H et al. Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis. J Natl Med Assoc. 2005; 97(8): 1120-6.
54. Quinn MA, Gough AK, Green MJ et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford). 2006; 45(4): 478-80.
55. Mottonen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis. 1988; 47(8): 648-53.
56. van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol. 1995; 34 Suppl 2: 74-8.
57. Dorner T, Egerer K, Feist E, Burmester GR. Rheumatoid factor revisited. Curr Opin Rheumatol. 2004; 16(3): 246-53.
58. Bas S, Perneger TV, Seitz M, Tiercy JM, Roux-Lombard P, Guerne PA. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford). 2002; 41(7): 809-14.
59. Vittecoq O, Pouplin S, Krzanowska K et al. Rheumatoid factor is the strongest predictor of radiological progression of rheumatoid arthritis in a three-year prospective study in community-recruited patients. Rheumatology (Oxford). 2003; 42(8): 939-46.
60. Jansen LM, van Schaardenburg D, van der HorstBruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibody in early arthritis. J Rheumatol 2003; 30: 1691-5.
61. Vencovsky J, Machacek S, Sedova L et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis. 2003; 62(5): 427-30.
62. Meyer O, Labarre C, Dougados M et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis. 2003; 62(2): 120-6.
63. Berglin E, Johansson T, Sundin U et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006; 65(4): 453-8.
64. Greiner A, Plischke H, Kellner H, Gruber R. Association of anti-cyclic citrullinated peptide antibodies, anticitrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis. Ann N Y Acad Sci. 2005; 1050: 295-303.